Hormonal
Homozygosity for the C allele at position -174 of the IL-6 gene is associated with lower plasma IL-6 levels, increased insulin sensitivity, and lower postload glucose levels compared to carriers of the G allele.
This research highlights that your genetics, specifically the IL-6 gene, influence how sensitive you are to insulin. If you carry the G allele, you may have higher baseline inflammation and lower insulin sensitivity. While you cannot change your genes, this knowledge underscores the importance of maintaining healthy body composition and managing inflammation, as these factors interact with your genetic predisposition to affect metabolic health.
Subjects homozygous for the C allele at position –174 of the IL-6 gene (SfaNI genotype), associated to lower plasma IL-6 levels, showed significantly lower integrated area under the curve of serum glucose concentrations (AUC glucose) after an oral glucose tolerance test, lower blood glycosylated hemoglobin, lower fasting insulin levels, lower total and differential white blood cell count (a putative marker of peripheral IL-6 action), and an increased insulin sensitivity index than carriers of the G allele, despite similar age and body composition.
Why this rating
Observational study with a small sample size (n=32) and healthy subjects, limiting generalizability to diabetic or obese populations.
Source
Interleukin-6 gene polymorphism and insulin sensitivity.
José Manuel Fernández‐Real et al. · Diabetes · 2000
DOI 10.2337/diabetes.49.3.517
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →